Who we are

From the start, we’ve done things differently — leading with a human-centric culture, working side-by-side with our clients and turning legal challenges into business-executable decisions.

Learn more

Achieving our Commitment

Diversity is integral to our commitment to delivering excellence to our clients and our community. As a firm, we champion this commitment through our DEI Framework and DEI Committee.

Learn more

Join our Student Program

At WD, we involve our students directly in everything we do. Dive into a range of legal work, build client relationships and receive valuable mentorship from our team.

Learn more

Be part of a premier law firm

We’re looking for team members who take a skilled approach to their work, relish finding new paths to successful outcomes and seek professional growth in a flexible firm culture.

Learn more

Find a Lawyer

There are no results for “”

October 27, 2023

Wildeboer Dellelce Represents Special Committee of Mindset Pharma Inc. in Sale to Otsuka Pharmaceutical Co., Ltd.

Otsuka Pharmaceutical Co., Ltd. (“Otsuka”) completed the acquisition of all of the issued and outstanding common shares in the capital of Mindset Pharma Inc. (“Mindset”) for cash consideration having a transaction value of approximately $80 million. The transaction was carried out through an arrangement under the Business Corporations Act (British Columbia).

Mindset Pharma is a drug discovery and development company focused on creating optimized and patentable best-in-class innovative next-generation psychedelic medicines to treat neurological and psychiatric disorders with unmet needs.

Otsuka is a global healthcare company that researches, develops, manufactures, and markets innovative products, with a focus on pharmaceutical products to meet unmet medical needs and nutraceutical products for the maintenance of everyday health.

Wildeboer Dellelce LLP acted for the Special Committee of the Board of Directors of Mindset in connection with the transaction, with a team that included Sanjeev Patel, Joel Fraser and Andrew Jensen (Corporate/Securities) and Jesse Brodlieb (Tax).